Time filter

Source Type

Huntingdon, United Kingdom

Schmidt V.,University of Liverpool | McEwan N.,University of Liverpool | Volk A.,The Royal Veterinary College | Helps J.,Schering | And 2 more authors.
Veterinary Dermatology | Year: 2010

This double-blind randomized placebo-controlled trial indicates that Phytopica™ can be an effective glucocorticoid sparing agent in canine atopic dermatitis (AD). Twenty-two dogs with perennial AD [Canine Atopic Dermatitis with Severity Index (CADESI-03) ≥ 60] were given 200 mg/kg Phytopica™ or an identical placebo in food once daily for 56 days. All dogs were initially given 0.4 mg/kg methyl-prednisolone once daily, which was then adjusted according to the daily pruritus score (0-100 mm visual analogue scale). The cumulative dose and pruritus score were lower in the Phytopica™ than the placebo group. There were statistically significant time and treatment effects for the methyl-prednisolone dose and pruritus score, but there were no significant differences between the Phytopica™ and placebo groups in the proportion of dogs that achieved a > 50% reduction in dose or pruritus scores at day 56; the mean CADESI-03 scores at days 0, 28 and 56; the numbers achieving >50% reduction in CADESI-03 at days 28 and 56; or in the owners' global efficacy score at days 28 and 56. Adverse events included diarrhoea (three Phytopica™ and one placebo treated dog), polyuria/polydipsia (three dogs in each group), and polyphagia, intermittent anorexia and panting (one dog each in the placebo group). None of these by themselves required withdrawal of treatment. © 2010 The Authors. Journal compilation © 2010 ESVD and ACVD.

Russell P.J.,Colworth Science Park | Swindells C.,Phytopharm plc
Food and Chemical Toxicology | Year: 2012

The chemical composition of a solvent extract of Hoodia gordonii termed '. H. gordonii extract' has been characterised by hyphenated chromatographic methods and traditional analytical techniques. The extract consists of a mixture of steroid glycosides, fatty acids, plant sterols and polar organic material. High performance liquid chromatography (HPLC) with ultra violet (UV) and mass spectrometric (MS) detection was used to quantify and confirm the identity of a number of steroid glycosides (73.7% w/w) present in the extract. Gas chromatography (GC) with MS and flame ionisation detection (FID) was applied to determine the fatty acid (3.12% w/w) sterol (0.39% w/w) and alcohol (0.03% w/w) content of a saponified sample of the extract. Polar organic material was quantified by gravimetric methodology using C 18 SPE separation and was determined to be a minimum of 3% w/w. Moisture content was measured by Karl Fischer coulometric titration (0.81% w/w).The protein content was investigated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) with SYPRO Ruby staining and a negative result was determined with a limit of detection of <0.001%w/w of protein per band. The chemical composition of the extract remained stable for 19. months when stored in re-sealable plastic bags at ambient (21-24 °C) temperature and <60% relative humidity. © 2011 Elsevier Ltd.

Scott A.D.,Colworth Science Park | Orsi A.,Formerly Phytopharm plc. | Ward C.,Phytopharm plc | Bradford R.,Colworth Science Park
Food and Chemical Toxicology | Year: 2012

Hoodia gordonii extract consists of a mixture of steroid glycosides, fatty acids, plant sterols and alcohols. As part of the overall safety assessment H. gordonii extract was assessed for genotoxicity in two assays in vitro: a bacterial mutation assay; and a gene mutation assay using mouse lymphoma cells. H. gordonii extract showed no evidence of genotoxic activity in either of these assays. In addition, H. gordonii extract was assessed for mutagenic activity in a bone marrow micronucleus (MN) assay in the mouse, with 400. mg/kg selected as the high-dose group, based on observations in a dose-range-finding study. The group mean frequencies of micronucleated polychromatic erythrocytes of treated animals were similar to those of the vehicle control group, indicating H. gordonii extract to be non-genotoxic under the conditions of this test. All assays were performed in compliance with the Good Laboratory Practice Regulations and in accordance with standard guidelines for genotoxicity tests. H. gordonii extract was shown to be non-genotoxic in 3 independent assays (a bacterial mutation test, a gene mutation assay using mouse lymphoma cells and a bone marrow micronucleus assay in the mouse). © 2011 Elsevier Ltd.

Wang W.,Phytopharm plc | Russell P.J.,Colworth Science Park | Clark G.T.,Quotient Bioresearch Ltd. | Lewis D.,Quotient Bioresearch Ltd. | Cheng K.N.,Quotient Bioresearch Ltd.
Food and Chemical Toxicology | Year: 2012

Hoodia gordonii extract contains steroid glycosides, fatty acids, plant sterols and polar organic material. Certain steroid glycosides show appetite suppressant activities following oral ingestion. This study describes the validation of a bioanalytical method for the quantification of one of the steroid glycosides, H.g.-12 (∼10% (w/w) of the extract), in mouse, rat, rabbit and human plasma. The method utilises a liquid-liquid extraction with methyl-tert-butyl ether followed by chromatographic separation on a 2.1×50mm C 18 Genesis high performance liquid chromatography (HPLC) column and detection on a triple quadrupole mass spectrometer. Detection of H.g.-12 and its stable isotope internal standards is performed using positive TurboIonspray™ ionisation in multiple reaction monitoring mode. The validation procedure demonstrated assay sensitivity, linearity, accuracy, precision and selectivity over the calibration range of 0.5-150ng/mL in human plasma (500μL sample volume), 1.0-100ng/mL in rat and rabbit plasma (150μL sample volume) and 1.0-250ng/mL in mouse plasma (150μL sample volume) with good recoveries (≥77%). H.g.-12 was stable in plasma for ≥6months at -20°C, for up to 4h at ambient temperature (ca22°C) and after 3 freeze-thaw cycles. Plasma extracts were stable for up to 24h at ambient temperature. © 2010 Elsevier Ltd.

Phytopharm Plc | Date: 2011-04-12

The invention discloses therapeutic methods and uses of certain steroidal sapogenins, related compounds and derivatives thereof, in the treatment of non-cognitive neurodegeneration, non-cognitive neuromuscular degeneration, motor-sensory neurodegeneration or receptor dysfunction or loss in the absence of cognitive, neural and neuromuscular impairment.

Discover hidden collaborations